Near­ly a year af­ter his SPAC com­bines with EQRx, Eli Cas­din re­signs from board

About 11 months af­ter his in­vest­ment firm’s blank check com­pa­ny helped boost EQRx’s cash cof­fers by about $1.3 bil­lion, Eli Cas­din is out from the biotech’s board.

The day be­fore Thanks­giv­ing, he told EQRx’s board that he would re­sign at the end of that day, ac­cord­ing to an SEC fil­ing. The de­ci­sion “was not due to any dis­agree­ment with EQRx” re­lat­ing to the com­pa­ny’s “op­er­a­tions, poli­cies or prac­tices,” as the biotech out­lined in the pa­per­work with the agency.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER